Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00837707|
Recruitment Status : Unknown
Verified February 2009 by Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan.
Recruitment status was: Recruiting
First Posted : February 5, 2009
Last Update Posted : February 5, 2009
|Condition or disease||Intervention/treatment||Phase|
|Dyskinesia, Drug-Induced||Drug: aripiprazole||Phase 4|
Objective:A few case reports on the use of aripiprazole in neuroleptic-induced tardive dyskinesia have demonstrated positive effects. However its effectiveness in treatment of TD was still inconclusive. The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia.
Method: Subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from Taoyuan psychiatric center. Patients recruited would be treated with aripiprazole for cross-titration with previous antipsychotics in 8 weeks. We use AIMS, SAS, & BAS to assess the severity of TF and EPS. We record subjects' age, sex, and other factors which have influence at the treatment response. Subjects are assessed every two weeks in the first month and then monthly until six months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study|
|Study Start Date :||June 2008|
|Estimated Primary Completion Date :||August 2009|
|Estimated Study Completion Date :||February 2010|
- Drug: aripiprazole
Flexible dose: 5-30 mg/dayOther Name: Abilify
- Total scores of AIMS [ Time Frame: The change from baseline to study endpoint ]
- Total scores of PANSS [ Time Frame: The change from baseline to study endpoint ]
- Total scores of SAS [ Time Frame: The change from baseline to study endpoint ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00837707
|Contact: Chia-Hsiang Chan, M.D.||886-3-3698553 ext firstname.lastname@example.org|
|Taoyuan Mental Hospital||Recruiting|
|Taoyuan, Taiwan, 330|
|Contact: Chia-Hsiang Chan, M.D. 886-3-3698553 ext 2069 email@example.com|
|Principal Investigator: Chia-Hsiang Chan, M.D.|
|Study Chair:||Chia-Hsiang Chan, M.D.||Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan|